We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Tapan Panchal
LONDON--U.K.-based pharmaceutical company AstraZeneca PLC (AZN.LN) said Tuesday that it signed an agreement with U.S.-based Eli Lilly and Co. (LLY) to develop and commercialize AZD3293, an oral beta secretase cleaving enzyme for the treatment of Alzheimer's disease.
Alzheimer's is an illness that causes progressive memory decline.
Under the agreement, Lilly will pay AstraZeneca up to $500 million in development and regulatory milestone payments. AstraZeneca expects to receive the first milestone payment of $50 million in the first half of 2015. The companies will share all future costs and revenue equally from the development of AZD3293. AstraZeneca will be responsible for manufacturing AZD3293, while Lilly will lead the clinical development.
AstraZeneca said the agreement will have no impact on its 2014 core earnings per share.
Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
